{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:18:13Z","timestamp":1777519093314,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.clml.2021.11.001","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T21:08:40Z","timestamp":1636578520000},"page":"e321-e326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["COVID-19 Vaccine Responses in Patients With Plasma Cell Dyscrasias After Complete Vaccination"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8884-3085","authenticated-orcid":false,"given":"Mansi R.","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alissa","family":"Gabel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6916-1177","authenticated-orcid":false,"given":"Stephanie","family":"Beers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gratian","family":"Salaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis L.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.11.001_bib0001","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood-2016-09-692954","article-title":"MGUS to myeloma: a mysterious gammopathy of underexplored significance","volume":"128","author":"Dhodapkar","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2021.11.001_bib0002","first-page":"282","article-title":"Immunosuppression and infection in multiple myeloma","volume":"13","author":"Jacobson","year":"1986","journal-title":"Semin Oncol."},{"key":"10.1016\/j.clml.2021.11.001_bib0003","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/jcp.48.3.260","article-title":"Immunological factors and risk of infection in plateau phase myeloma","volume":"48","author":"Hargreaves","year":"1995","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.clml.2021.11.001_bib0004","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bjh.13532","article-title":"Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy","volume":"171","author":"Teh","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.11.001_bib0005","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.11.001_bib0006","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.11.001_bib0007","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.11.001_bib0008","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3026(21)00110-1","article-title":"Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma","volume":"8","author":"Bird","year":"2021","journal-title":"Lancet Haematol"},{"issue":"26","key":"10.1016\/j.clml.2021.11.001_bib0009","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood.2021011904","article-title":"Low neutralizing antibody responses against SARS-CoV-2 in elderly myeloma patients after the first BNT162b2 vaccine dose","volume":"137","author":"Terpos","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.11.001_bib0010","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.11.001_bib0011","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.11.001_bib0012","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.11.001_bib0013","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.11.001_bib0014","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.11.001_bib0015","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01694-20","article-title":"Development and validation of the Elecsys Anti-SARS-CoV-2 immunoassay as a highly specific tool for determining past exposure to SARS-CoV-2","volume":"58","author":"Muench","year":"2020","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.clml.2021.11.001_bib0016","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jinf.2020.06.067","article-title":"SARS-CoV-2 detection, viral load and infectivity over the course of an infection","volume":"81","author":"Walsh","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.clml.2021.11.001_bib0017","article-title":"Prior COVID-19 infection and antibody response to single versus double dose mRNA SARS-CoV-2 vaccination","author":"Ebinger","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.clml.2021.11.001_bib0018","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1056\/NEJMc2101667","article-title":"Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine","volume":"384","author":"Krammer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.11.001_bib0019","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41564-020-00841-4","article-title":"Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets","volume":"6","author":"Singh","year":"2021","journal-title":"Nat Microbiol"},{"issue":"27","key":"10.1016\/j.clml.2021.11.001_bib33","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","author":"Khoury","year":"2021","journal-title":"Nature Medicine"},{"key":"10.1016\/j.clml.2021.11.001_bib0021","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ccell.2021.06.014","article-title":"Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma","volume":"39","author":"Van Oekelen","year":"2021","journal-title":"Cancer Cell"},{"issue":"23","key":"10.1016\/j.clml.2021.11.001_bib0022","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.11.001_bib0023","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bjh.15433","article-title":"Infectious and immunological sequelae of daratumumab in multiple myeloma","volume":"185","author":"Johnsrud","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.11.001_bib0024","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/bloodadvances.2020003880","article-title":"Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias","volume":"5","author":"Branagan","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.clml.2021.11.001_bib0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","article-title":"Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network","volume":"35","author":"Ludwig","year":"2021","journal-title":"Leukemia"},{"issue":"10303","key":"10.1016\/j.clml.2021.11.001_bib0026","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0140-6736(21)01694-9","article-title":"Safety and Immunogenicity Report from the Com-COV Study \u2013 a single-blind randomised non-inferiority trial comparing heterologous and homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine","volume":"398","author":"Liu","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2021.11.001_bib0027","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1473-3099(21)00059-1","article-title":"Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products","volume":"21","author":"Romero","year":"2021","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.clml.2021.11.001_bib0028","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1186\/s12879-020-05507-4","article-title":"The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial","volume":"20","author":"Gharebaghi","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.clml.2021.11.001_bib0029","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-020-00934-x","article-title":"A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward","volume":"13","author":"Wang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2021.11.001_bib0030","article-title":"COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers","author":"Hultcrantz","year":"2020","journal-title":"medRxiv"},{"issue":"385","key":"10.1016\/j.clml.2021.11.001_bib0020","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1056\/NEJMc2111462","article-title":"Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients","volume":"13","author":"Hall","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.11.001_bib0032","doi-asserted-by":"crossref","DOI":"10.3201\/eid2701.203611","article-title":"Intrafamilial exposure to SARS-CoV-2 associated with cellular immune response without seroconversion, France","volume":"27","author":"Gallais","year":"2021","journal-title":"Emerg Infect Dis."},{"issue":"11","key":"10.1016\/j.clml.2021.11.001_bib35","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ccell.2021.09.015","article-title":"Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma","volume":"39","author":"Aleman","year":"2021","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.clml.2021.11.001_bib34","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","author":"Kumar","year":"2016","journal-title":"Lanc. Oncol."}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021024228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021024228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:39:12Z","timestamp":1761871152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021024228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S2152265021024228"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.11.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 Vaccine Responses in Patients With Plasma Cell Dyscrasias After Complete Vaccination","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}